AEON Biopharma

Present pricing power is limited. As a prospective biosimilar, ABP‑450 would likely compete on net price and operational fit rather than premium pricing. AEON’s thesis highlights protecting provider cost recovery via therapeutic‑only ASP and parity on dosing to reduce friction, not raising prices.

This positioning would constrain absolute pricing power and make volume the key lever. Prior data indicate Botox remains the sole on‑label option in chronic migraine, reinforcing incumbent power; AEON must discount and provide logistical parity to win share.

The absence of revenue and negative TTM free cash flow further reduce latitude to test price. Until biosimilarity, extrapolation and payer coverage are secured, we assume minimal pricing power.